Core Viewpoint - Rhein Biotech is undergoing a change in control, with its major shareholder transferring control to Guangzhou Defu Nutrition, effective from December 24, 2023, after a suspension of trading since December 10, 2023 [1][3]. Shareholder Changes - The controlling shareholder Qin Benjun signed several agreements with Guangzhou Defu Nutrition on December 22, 2023, including a framework agreement for control change and share transfer [3]. - Qin Benjun will transfer 8.09% of his shares in Rhein Biotech to Guangzhou Defu Nutrition and will relinquish voting rights for 25.50% of his shares while retaining voting rights for 3% [4]. - The total transaction value is 646 million yuan, with a share transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9, 2023 [4]. Post-Transaction Shareholding Structure - After the transaction, Qin Benjun will hold 28.50% of Rhein Biotech's shares and 4.14% of the voting rights, while Guangzhou Defu Nutrition will hold 8.09% of the shares and 11.17% of the voting rights [5]. - Guangzhou Defu Nutrition was established on December 2, 2025, by Defu Capital and currently has not engaged in any actual business activities [5]. Strategic Intentions - Rhein Biotech aims to leverage Defu Capital's extensive resources in the healthcare sector to enhance its operational efficiency and governance structure [6]. - The company plans to expand its industry chain through acquisitions, specifically targeting the nutritional supplement sector, to create a closed-loop supply chain from raw materials to formulation solutions [7]. Acquisition Details - Rhein Biotech has signed agreements to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through share issuance, which will be funded by issuing shares to Guangzhou Defu Nutrition [7]. - This acquisition is expected to enhance Rhein Biotech's capabilities in the nutritional supplement market, particularly in the area of fortified food products [8]. Financial Overview of Beijing Jinkangpu - As of September 30, 2025, Beijing Jinkangpu reported total assets of 593 million yuan and a net profit of 40.33 million yuan for the first three quarters of 2025 [8]. - The company is a leading supplier of nutritional supplements for infant formula manufacturers, indicating a strong market position [8]. Financial Performance of Rhein Biotech - As of September 30, 2025, Rhein Biotech's total assets were 4.985 billion yuan, with a net profit of 70.40 million yuan for the first three quarters of 2025 [10]. - The company has shown a consistent growth trajectory in its financial performance, with total liabilities of 1.823 billion yuan [10].

Group 1 - Rhine Biotech plans to change control by acquiring 80% stake in Beijing Jinkangpu, with the current controlling shareholder transferring 60 million shares (8.09% of total shares) and relinquishing voting rights on 189 million shares (25.5% of total shares) [1][2] - The acquisition is expected to be completed after the transfer of shares and the board of directors' restructuring, making Guangzhou Defu Nutrition the new controlling shareholder [1] - The specific transaction price for the acquisition of Beijing Jinkangpu is yet to be determined, and the transaction is not expected to constitute a major asset restructuring [2] Group 2 - Shida Shenghua and Bertli are planning to list H-shares on the Hong Kong Stock Exchange, with both companies considering the interests of existing shareholders and market conditions [3] - The listing process for both companies is in discussion with relevant intermediaries, and specific details have not yet been finalized [3] Group 3 - Ningbo Huaxiang's subsidiary has signed a contract for the production of robot joints, which is expected to positively impact future operating performance starting from January 2026 [4] Group 4 - Ningbo Port plans to acquire 100% of the equity of Zhoushan Port Comprehensive Bonded Zone Terminal for 706 million yuan to resolve competition issues [7] - The company aims to enhance its operational capabilities through this acquisition [7] Group 5 - Huaxin Building Materials' major shareholder plans to increase its stake in the company by 200 to 400 million yuan within six months [12] - The shareholder has secured a loan commitment of up to 360 million yuan from a bank to facilitate this purchase [12]

Group 1 - The company announced a control change agreement where Qin Benjun will transfer 60 million shares (8.09%) to Guangzhou Defu Nutrition and relinquish voting rights for 189,141,310 shares (25.50%), retaining voting rights for 22,248,282 shares (3.00%) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers [1] - The company plans to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance to Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment [1] Group 2 - The target company specializes in the formulation, production, testing, sales, and technical services of food nutrition fortifiers, serving various sectors including dairy products and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier industry, supplying to numerous infant formula manufacturers [2] - The acquisition will enhance the company's business structure, creating a closed-loop industry chain from raw materials to formulation solutions, thereby improving operational stability and risk resistance [2] Group 3 - The company's stock will resume trading on December 24, 2025 [3]

Group 1 - The company announced a change in control agreement where Qin Benjun will transfer 60 million shares (8.09%) to Guangzhou Defu Nutrition and relinquish voting rights for 189,141,310 shares (25.50%), retaining voting rights for 22,248,282 shares (3.00%) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [1] - The company plans to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance to Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment [1] Group 2 - The target company specializes in the formulation, production, testing, sales, and technical services of food nutrition fortifiers, serving various sectors including dairy products and functional beverages [2] - The target company is a leading enterprise in the food nutrition fortifier industry, supplying to numerous infant formula manufacturers [2] - The acquisition will enhance the company's business structure, making it more diversified and improving operational stability and risk resistance [2] Group 3 - The company's stock will resume trading on December 24, 2025 [3]

（文章来源：证券日报） 证券日报网讯 12月23日，莱茵生物发布公告称，公司第七届董事会第十次会议审议通过《关于公司符 合发行股份购买资产并募集配套资金暨关联交易条件的议案》等多项议案。 ...

Core Viewpoint - The company is undergoing a significant change in control and is expanding its business into the food nutrition fortifier sector through the acquisition of Beijing Jinkangpu Food Technology Co., Ltd. Group 1: Control Change - The company's controlling shareholder, Qin Benjun, has signed agreements to transfer 60 million shares (8.09% of total shares) to Guangzhou Defu Nutrition and will relinquish voting rights for 189 million shares (25.50% of total shares), retaining voting rights for 22.2483 million shares (3.00% of total shares) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and LIZHENFU as the joint actual controllers [1] Group 2: Acquisition Details - The company has signed agreements to issue shares to acquire 80% of Beijing Jinkangpu, while also raising funds through share issuance to purchase an additional 15.50% stake from individual shareholders [1] - Beijing Jinkangpu specializes in the formulation, production, and sales of food nutrition fortifiers, serving as a leading supplier for infant formula manufacturers in China [2] Group 3: Strategic Benefits - The acquisition will allow the company to expand its business into the food nutrition fortifier sector, creating a closed-loop industry chain from raw materials to formulation solutions [2] - The partnership with Beijing Jinkangpu is expected to enhance the company's product coverage in the dairy sector and facilitate international expansion through its global sales network [2] - Post-transaction, Beijing Jinkangpu's financials will be consolidated into the company's reports, improving asset scale, revenue, and net profit, thereby diversifying income sources and enhancing operational stability [3]

Group 1 - The controlling shareholder of the company, Qin Benjun, plans to transfer 60 million shares (8.09% of total share capital) to Guangzhou Defu Nutrition and will relinquish voting rights for 189,141,310 shares (25.50% of total share capital), retaining 3.00% voting rights [1] - Guangzhou Defu Nutrition will become the controlling shareholder of the company, with Hou Ming and Li Zhenfu as the joint actual controllers [1] - The company intends to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance and raise additional funds for purchasing 15.50% equity from natural shareholders Li Yang and Song Jun, as well as covering intermediary fees, transaction taxes, and supplementing working capital [1] Group 2 - The target company specializes in the formulation, production, testing, sales, technological innovation, and services of food nutrition fortifiers, widely used in dairy products, functional beverages, complementary foods, medical foods, and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier sector, supplying nutrition fortifiers to numerous infant formula manufacturers both domestically and internationally [2] - The acquisition will allow the listed company to expand its industrial chain into the nutrition fortifier compounding field, creating a closed-loop from upstream raw materials to downstream formulation solutions, enhancing business synergy and stability [2]

Group 1 - The core point of the article is that Rhine Biology (002166.SZ) is undergoing significant changes in its ownership structure and is planning to acquire a majority stake in Beijing Jinkangpu Food Technology Co., Ltd. [1] - The controlling shareholder, Qin Benjun, intends to transfer 60 million shares (8.09% of total share capital) to Guangzhou Defu Nutrition and will relinquish voting rights for 189,141,310 shares (25.50% of total share capital), retaining only 3.00% voting rights [1] - Following this transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [1] Group 2 - The target company specializes in the formulation, production, testing, sales, technological innovation, and services of food nutrition fortifiers, which are widely used in dairy products, functional beverages, complementary foods, medical foods, and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier sector, supplying nutrition fortifiers to numerous infant formula manufacturers both domestically and internationally [2] - This acquisition will allow the listed company to expand its industrial chain into the nutrition fortifier compounding field, creating a closed-loop from upstream raw materials to downstream formulation solutions, enhancing business synergy and stability [2]

此外，莱茵生物拟通过发行股份的方式向德福金康普控股有限合伙企业和厦门德福金普投资合伙企业 （有限合伙）购买其合计持有的北京金康普食品科技有限公司（以下简称"北京金康普"）80%股权。同 时拟向广州德福营养发行股份募集配套资金，用于购买北京金康普股东李洋、宋军15.5%股权、支付中 介费用、交易税费和补充流动资金。 北京商报讯（记者 马换换 李佳雪）12月23日晚间，莱茵生物（002166）披露公告称，广州德福营养投 资合伙企业（有限合伙）（以下简称"广州德福营养"）将成为公司控股股东，侯明和LIZHENFU将成为 公司共同实际控制人。公司股票将于12月24日起复牌。 公告显示，广州德福营养与莱茵生物控股股东、实际控制人秦本军签订《控制权变更框架协议》《股份 转让协议》和《表决权放弃协议》，约定秦本军向广州德福营养协议转让其所持有的公司6000万股股份 （比例为8.09%），放弃1.89亿股股份表决权（比例为25.5%），保留2224.83万股股份表决权（比例为 3%）。 ...

Core Viewpoint - The company, Rhein Biotech, plans to acquire an 80% stake in Beijing Jinkangpu Food Technology Co., Ltd., a leading provider of nutritional fortifiers for infant formula, thereby expanding its industry chain into the nutritional fortifier compounding sector [1] Group 1: Acquisition Details - Rhein Biotech intends to issue shares to Defu Jinkangpu and Xiamen Defu Jinkangpu to purchase their combined 80% stake in Beijing Jinkangpu [1] - The transaction is still pending completion of auditing and evaluation work [1] Group 2: Strategic Implications - The acquisition will create a closed-loop industry chain from upstream raw materials to downstream formulation solutions in the nutritional fortifier sector [1] Group 3: Shareholder Changes - On December 22, Guangzhou Defu Nutrition signed an agreement with the company's original controlling shareholder, Qin Benjun, to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, retaining voting rights for 3% [1] - Following the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as co-controlling persons [1] - Guangzhou Defu Nutrition, Defu Jinkangpu, and Xiamen Defu Jinkangpu are related entities under common control [1] Group 4: Stock Resumption - The company's stock will resume trading on December 24 [1]